News

Employees of JPMorgan Chase are suing the company, alleging that its prescription drug plan, overseen by CVS Health, has been paying exorbitant prices for medications. This lawsuit is part of a growing trend of similar cases against major employers, raising questions about the role of employers and pharmacy benefit managers in the rising costs of healthcare in the US.

Elon Musk is facing criticism from investors for his divided attention between Tesla and his role in the Trump administration, which has coincided with protests, vandalism, and declining sales in Europe. Despite support from some conservatives, investor confidence remains low due to Musk's absence from Tesla and the lack of clarity on his plans for the company.

Berkshire Hathaway has paused its share buyback program, despite its stock nearing an all-time high and outperforming the S&P 500 this year. The company's strong performance and high valuation may lead to continued abstinence from buybacks, potentially impacting future financial strategies and investor sentiment.

The U.S. stock market experienced significant volatility this past week, with the S&P 500 dropping over 10% from its February highs due to investor fears surrounding President Donald Trump's tariff hikes and a potential global slowdown. Despite the turmoil, the market rebounded on Friday, with the Dow Jones gaining over 200 points as utilities, tech, and energy stocks rallied.

On March 14, 2025, Cathie Wood's Ark Invest made significant trades, buying shares in GitLab, Intellia Therapeutics, and Ibotta, while selling shares in UiPath, Roblox, Prime Medicine, Repare Therapeutics, and CareDx. These trades reflect Ark Invest's continued focus on innovative companies across various sectors.